Profil
Mythili Koneru currently works at Legend Biotech Corp., as Chief Medical Officer from 2023.
Dr. Koneru also formerly worked at Eli Lilly & Co., as Senior Medical Director-Early Phase Clinical and Marker Therapeutics, Inc., as Chief Medical Officer from 2019 to 2023.
Dr. Koneru received her undergraduate degree from The University of Chicago, doctorate degree from New York University, and doctorate degree from Robert Wood Johnson Medical School.
Aktive Positionen von Mythili Koneru
| Unternehmen | Position | Beginn |
|---|---|---|
| LEGEND BIOTECH CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 11.04.2023 |
Ehemalige bekannte Positionen von Mythili Koneru
| Unternehmen | Position | Ende |
|---|---|---|
| MARKER THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 09.04.2023 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.02.2019 |
Ausbildung von Mythili Koneru
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Marker Therapeutics, Inc.
Marker Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cell based immune therapeutics and vaccines for cancer treatment | Health Technology |
The University of Chicago
The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University
New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Robert Wood Johnson Medical School
Robert Wood Johnson Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Legend Biotech Corp.
Legend Biotech Corp. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which engages in the discovery and development of novel cell therapies for oncology | Health Technology |
















